Supplementary Data from Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Year: 2023
Type: supplementary-materials
Abstract: Supplement (adjusted per last reviewer comment).
Authors: Naval Daver, Guillermo Garcia-Manero, Sreyashi Basu, Prajwal C. Boddu, Mansour Alfayez, Jorge E. Cortes, Marina Konopleva, Farhad Ravandi-Kashani, Elias Jabbour, Tapan Kadia, Graciela M. Nogueras-Gonzalez, Jing Ning, Naveen Pemmaraju, Courtney D. DiNardo, Michael Andreeff, Sherry A. Pierce, Tauna Gordon, Steven M. Kornblau, Wilmer Flores, Zainab Alhamal, Carlos Bueso-Ramos, Jeffrey L. Jorgensen, Keyur P. Patel, Jorge Blando, James P. Allison, Padmanee Sharma, Hagop Kantarjian
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362617266